CDNA
CareDx, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$67.08
+4.81%Year over year
Reported trailing growth
- Revenue
- +34.4%
- EBITDA
- +152.6%
- EBIT
- —
- EPS
- +90.4%
- Free cash flow
- +616.0%
- Operating cash flow
- +428.5%
Forward estimates
Based on analyst estimates
- Revenue
- +11.4%
- EBITDA
- +510.2%
- EPS
- -46.4%
Three-year CAGR
- Revenue
- +5.7%
- EBITDA
- +86.3%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +14.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026